{
    "nct_id": "NCT00702780",
    "title": "Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2014-05-13",
    "description_brief": "This study aimed to test whether escitalopram would slow the brain atrophy in patients with mild to moderate AD over the 52-week period.",
    "description_detailed": "* Study institutions: Four university hospitals in Korea\n* Design: Multi-center, randomized, placebo-controlled, double-blind clinical trial\n* Subjects: 74 probable Alzheimer's disease patients who have been taking donepezil at stable dose within 2 months (Escitalopram 37 : Placebo 37)",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Escitalopram",
                    "description": "escitalopram 20mg qd"
                },
                {
                    "id": "FG001",
                    "title": "Placebo",
                    "description": "placebo 20mg qd"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "37"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "37"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "28"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "9"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "8"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Escitalopram",
                    "description": "escitalopram 20mg qd"
                },
                {
                    "id": "BG001",
                    "title": "Placebo",
                    "description": "placebo 20mg qd"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "28"
                        },
                        {
                            "groupId": "BG001",
                            "value": "29"
                        },
                        {
                            "groupId": "BG002",
                            "value": "57"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74.33",
                                            "spread": "7.12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "74.82",
                                            "spread": "9.19"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "74.58",
                                            "spread": "8.17"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "36"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "13"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "21"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "% Change of Hippocampus Volume",
                    "populationDescription": "The analysis was performed for per-protocol (PP) population, which included participants who had both baseline and follow-up MRI scan suitable for analysis.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "percentage of change",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Escitalopram",
                            "description": "escitalopram 20mg qd"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "placebo 20mg qd"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "28"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "29"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-7.63",
                                            "spread": "7.32"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-7.28",
                                            "spread": "5.76"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "% Change of Whole Brain Volume",
                    "populationDescription": "The analysis was performed for per-protocol (PP) population, which included participants who had both baseline and follow-up MRI scan suitable for analysis.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "percentage of change",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Escitalopram",
                            "description": "escitalopram 20mg qd"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "placebo 20mg qd"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "28"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "29"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-3.27",
                                            "spread": "2.69"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-2.30",
                                            "spread": "3.08"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "Baseline, and 2, 4, 8, 16, 28, 40, 52 weeks after baseline.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Escitalopram",
                    "description": "Escitalopram 20mg qd",
                    "seriousNumAffected": 2,
                    "seriousNumAtRisk": 37,
                    "otherNumAffected": 13,
                    "otherNumAtRisk": 37
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "Placebo 20mg qd",
                    "seriousNumAffected": 3,
                    "seriousNumAtRisk": 37,
                    "otherNumAffected": 7,
                    "otherNumAtRisk": 37
                }
            ],
            "seriousEvents": [
                {
                    "term": "Jaundice",
                    "organSystem": "Hepatobiliary disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "Death by traffic accident",
                    "organSystem": "Social circumstances",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "Cerebral hemorrhage",
                    "organSystem": "Vascular disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "dizziness",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "anorexia",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "constipation",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "cough",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "bronchitis",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "somnolence",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "tremor",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "violent behavior",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "urinary incontinence",
                    "organSystem": "Renal and urinary disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "hypoglycemia",
                    "organSystem": "Endocrine disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 37
                        }
                    ]
                },
                {
                    "term": "cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 37
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 37
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": true,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Young Min Choe",
                "organization": "Seoul National University Hospital",
                "email": "howlow44@daum.net",
                "phone": "82-2-2072-1730"
            }
        }
    },
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "Escitalopram (SSRI; small-molecule)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests escitalopram but the drug is a selective serotonin reuptake inhibitor (SSRI) that acts on the serotonin transporter (SERT) \u2014 an antidepressant/anxiolytic small molecule, not a biologic targeting Alzheimer pathology (amyloid or tau). \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Act: Key extracted details \u2014 drug: escitalopram (small-molecule SSRI); design: multi-center, randomized, placebo-controlled, double-blind; objective (per description): test whether escitalopram slows brain atrophy over 52 weeks. Because escitalopram\u2019s known mechanism and clinical indications are to treat mood/anxiety symptoms (not to directly target AD pathology), the best-fit category is 'neuropsychiatric symptom improvement'. \ue200cite\ue202turn0search12\ue202turn0search0\ue201",
        "Web search results (most relevant sources found): 1) PubMed review: escitalopram primarily targets the serotonin transporter (SERT) and has effects on serotonin neurotransmission and neuroadaptive/neuroplastic changes. \ue200cite\ue202turn0search0\ue201 2) DrugBank/Drug summary: describes escitalopram\u2019s S-enantiomer properties and mechanism as a selective SERT inhibitor (small-molecule). \ue200cite\ue202turn0search4\ue201 3) Wikipedia/drug summary: lists escitalopram as an FDA\u2011approved antidepressant/ anxiolytic and summarizes pharmacology (high SERT selectivity). \ue200cite\ue202turn0search12\ue201",
        "Reflect: Although the investigators tested a disease-progression endpoint (brain atrophy), escitalopram is not a disease-targeted biologic or small molecule (by the definition here it does not target amyloid/tau). It is primarily used to treat neuropsychiatric symptoms (depression/anxiety) and any hypothesised slowing of atrophy would be an indirect or exploratory/neuroprotective effect, not a direct anti\u2011amyloid/tau mechanism \u2014 therefore classification as 'neuropsychiatric symptom improvement' is most appropriate. \ue200cite\ue202turn0search0\ue202turn0search12\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational drug is escitalopram, a selective serotonin reuptake inhibitor (SSRI) whose primary molecular target is the serotonin transporter (SERT) \u2014 a component of serotonergic neurotransmission. This indicates the intervention acts on a neurotransmitter system rather than directly on amyloid, tau, ApoE, inflammation, vasculature, etc. \ue200cite\ue202turn0search4\ue202turn0search3\ue201",
        "Act: Key extracted details \u2014 drug: escitalopram (small\u2011molecule SSRI) targeting SERT; trial design: multi\u2011center, randomized, placebo\u2011controlled, double\u2011blind; objective included testing whether escitalopram slows brain atrophy over 52 weeks but the drug\u2019s known mechanism is modulation of serotonin reuptake and treatment of neuropsychiatric symptoms (depression/anxiety). Mapping the molecular target (SERT) to CADRO gives 'D) Neurotransmitter Receptors'. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "Reflect: This classification fits because CADRO category D covers interventions acting on neurotransmitter systems/receptors/transporters (serotonergic pathway/SERT). Although the trial measured a disease\u2011progression endpoint (brain atrophy), the mechanism of escitalopram is not a direct anti-amyloid or anti\u2011tau disease\u2011modifying action but modulation of neurotransmission and neuropsychiatric symptoms \u2014 therefore D is the most specific CADRO category. (Note: some exploratory data link serotonin signaling to A\u03b2 biology in certain studies, but that does not change the primary molecular target classification.) \ue200cite\ue202turn0search6\ue202turn0search5\ue201",
        "Web search results (key sources referenced): 1) PubMed review describing escitalopram\u2019s primary target as the serotonin transporter (SERT) and its allosteric effects. \ue200cite\ue202turn0search4\ue201 2) DrugBank drug entry summarizing escitalopram mechanism as SERT inhibition (orthosteric + allosteric activity). \ue200cite\ue202turn0search3\ue201 3) PubMed entry for the multicenter randomized placebo\u2011controlled double\u2011blind escitalopram trial in AD (primary outcome: hippocampal/whole brain atrophy over 52 weeks). \ue200cite\ue202turn0search1\ue201 4) Clinical trial / controlled study reporting escitalopram effects on CSF A\u03b242 in older adults (exploratory mechanistic link between serotonin signaling and A\u03b2 biology). \ue200cite\ue202turn0search6\ue201 5) Systematic/review summaries of escitalopram efficacy and pharmacology in depression/anxiety. \ue200cite\ue202turn0search5\ue201"
    ]
}